To investigate the effect caused by Zhikang Capsule on ulcerative colitis patients’ serum TNF-α, IL-6, CRP. Methods:A total of 98 patients with ulcerative colitis were randomly divided into observation group （49 cases） and control group （49 cases）. The control group received routine treatment, while the observation group received conventional treatment combined Zhikang Capsule. Results:Observation group’s total effective rate （95.92%） was significantly higher than control group （83.67%） （P<0.05）. After treatment, the serum levels of TNF-α in observation group patients was （23.5±2.7） ng / L, IL-6 （31.6±1.3） ng / L, CRP （3.2±0.9） mg / L, lower than control group’s serum TNF-α （47.2±5.8） ng / L, IL-6 （47.3±4.5） ng / L, CRP （5.1±1.2） mg / L, the differences were statistically significant （P<0.01）. After treatment, the observation group’s FIB was （3.0±0.8） g / L, PLT （209.7±45.3） 109 / L, MPV （9.0±1.4） fL lower than the control group’s FIB （4.1±0.3） g / L, PLT （236.1±39.5） 109 / L, MPV （12.1±1.2） fL, the differences were statistically significant （P<0.01-0.05）. After treatment, the observation group’s PAGMax index was significantly higher than control group（P<0.05）, the observation group’s albumin （31.4±2.1） g / L was significantly higher than control group’s （28.1±2.0） g / L （P<0.01）. After treatment, the observation group quality of life score （82.3±9.2） was significantly higher than control group（76.4±7.8） （P<0.05）.Conclusion:Zhikang Capsule has good effect in the treatment of ulcerative colitis patients, which can reduce the serum levels of TNF-α, IL-6, CRP, relieve inflammatory reaction and the state of blood clotting, and improve the quality of life.